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ABSTRACT 
 
Introduction:   
Outpatient parenteral antimicrobial therapy (OPAT) is a common medical practice that can 
reduce hospital length-of-stay and improve patient satisfaction.1 Laboratory abnormalities and 
adverse drug reactions (ADRs) are potential complications of OPAT that may result in urgent 
care and emergency department visits, readmissions, or changes in antimicrobial therapy. 
Empirical therapy for diabetic foot infections (DFI) and osteomyelitis (OM) is frequently 
required, and choice of beta-lactams and combinations that have more favorable adverse drug 
effect profiles benefits patients and OPAT programs. The purpose of this study is to evaluate the 
type and timing of ADRs associated with common beta-lactams, and estimate the risk of ADRs 
during OPAT for beta-lactam therapies commonly used to treat DFI and OM.  
 
Methods:  
This was a cohort study of patients who were enrolled in the OPAT program at an academic 
medical center between January 2015 and September 2018. The primary outcome was time to 
first ADR during OPAT for any of the following medications: cefepime, ceftriaxone, ertapenem, 
meropenem, and piperacillin/tazobactam. The secondary outcomes were ADR types and 
frequencies observed among patients treated with beta-lactam alone or with concomitant 
vancomycin or daptomycin, and rates of hospital readmission and medication change due to 
ADR. 
 
Results:  
In this cohort, 178 OPAT patients received 193 OPAT courses, for a median duration of 42 days 
(IQR 38-50). Ertapenem was the most commonly prescribed beta-lactam (76 courses, 39%), 
followed by cefepime, (41, 21%), ceftriaxone (29, 15%), piperacillin/tazobactam (30, 16%) and 
meropenem (17, 9%). Approximately 40% (76) patients received concomitant vancomycin. ADR 
was documented in 53 patients (30%) and 55 courses of therapy (28%).  Kaplan-Meier-estimated 
risk of at least one ADR in the first 8 weeks of therapy was 40% (95% CI 29.1% to 
48.2%).  ADR resulted in 33 therapy changes and 8 readmissions.  
 
Conclusions: 
More than one-third of patients treated with beta-lactam therapies for treatment of DFI and/or 
OM are at risk of ADR within 8 weeks. ADRs that can lead to treatment changes and hospital 
readmissions are potential complications of patients enrolled in OPAT programs. When 
empirical therapy is required for treatment of DFI or OM, knowing the different safety profiles 
of beta-lactam therapies in an outpatient setting can assist clinicians in drug selection.   
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Outpatient parenteral antimicrobial therapy (OPAT) is an established practice that allows 
patients to receive intravenous therapy in the outpatient setting1. Since the 1970s, OPAT has 
played an important role in decreasing hospital length-of-stay in patients that are stable enough 
to receive intravenous antimicrobial therapy outside of the acute care setting2. An estimated 1 out 
of 1000 Americans today receive OPAT annually, and this number is expected to grow with the 
continuing shifts in the delivery of healthcare3. Advantages of OPAT include reduced hospital 
length-of-stay, potential cost savings, and patient satisfaction. Disadvantages of OPAT include 
reduced healthcare provider supervision and less environmental control, which can both lead to 
insufficient monitoring of OPAT patients and an increase in adverse events3. No evidence-based 
guidelines currently exist regarding the frequency of outpatient follow-up, patient education, or 
care transitions for patients treated with OPAT4,5. Therefore, patients receiving OPAT are 
potentially at increased risk of adverse events and hospital readmission3,5.  
 
The University of North Carolina Medical Center OPAT program was started in 2015, and 
provides multidisciplinary management of patients requiring intravenous antimicrobial therapy 
who are stable enough to be discharged. These patients are referred to the program by the 
infectious diseases (ID) inpatient services, then followed after discharge by a multidisciplinary 
team consisting of physicians, pharmacists, and nurses while they receive intravenous 
antimicrobial therapy from home. UNC OPAT patients are provided with protocolized laboratory 
monitoring and streamlined access to ID urgent care services. A primary aim of the program is to 
prevent hospital readmissions. 
 
Despite its clear benefits in decreased costs and patient satisfaction, OPAT can pose serious risks 
to patients due to its administration in a less monitored outpatient setting. Laboratory 
abnormalities are a frequent complication of antimicrobial therapy, as are drug reactions such as 
rash4,6,8. Thirty-day readmissions are common among patients, ranging from 17% to 27%, with 
ADRs accounting for up to 1 in 4 of these readmissions8. A review of the first 250 patients 
enrolled in the UNC OPAT program found that 1 in 4 patients (26%) experienced at least one 
adverse drug reaction (ADR) during therapy. Additionally, an ADR was the most common 
reason for ID urgent care visit6. ADRs experienced by those patients included liver dysfunction, 
kidney dysfunction, neutropenia, eosinophilia, thrombocytopenia, and rash. Of those patients 
who experienced an ADR from their OPAT regimen, ADRs were most common in patients 
receiving beta-lactam only therapy6. However, the types of ADRs and when these ADRs 
occurred in the course of therapy with specific beta-lactam therapies were not identified.   
 
Patients who are diagnosed with infections such as osteomyelitis (OM) or diabetic foot infection 
(DFI) are often candidates for OPAT enrollment due to the expected multiweek course of 
antimicrobial treatment.9 There are very few comparative efficacy studies of antimicrobials for 
DFI and OM to inform therapy selection. National guidelines recommend directing antimicrobial 
therapy against pathogens isolated from deep tissue or bone biopsies for patients with OM or 
DFI, but empirical therapy is frequently required.9 This could be due to an inability to obtain 
cultures or low microbiologic yield, and results in patients receiving empirical therapies for the 
entire course of treatment. In settings like this, clinicians’ choice of antimicrobial therapy is often 
guided by broad categories of agents that cover pathogens of particular interest, such as 
Pseudomonas or anaerobes (Table 1). Within those broad categories, choosing a beta-lactam 
therapy with a favorable safety profile facilitates completion of treatment without adverse effect, 
change in therapy, or hospital readmission.  
 
Table 1: Intravenous beta-lactam antibiotics therapy options for commonly suspected bacterial 
pathogens in DFI and OM 
 
 
 
The purpose of this study was to evaluate the type and timing of adverse drug reactions 
associated with commonly prescribed intravenous beta-lactams (ceftriaxone, cefepime, 
ertapenem, piperacillin/tazobactam, meropenem), and estimate the risk of ADRs during OPAT 
for these therapies commonly used to treat DFI and OM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infection involving 
Pseudomonas 
aeruginosa 
Infection involving 
other Gram 
negative pathogens  
(not Pseudomonas) 
Infection involving 
Methicillin-resistant 
Staphylococcus aureus 
Infection involving 
Anaerobes 
Piperacillin/       
tazobactam 
Cefepime 
Ceftazidime  
Meropenem 
Imipenem/cilastatin 
Aztreonam 
 
 
Ceftriaxone 
Ceftaroline  
Ertapenem 
Aztreonam  
 
Ceftaroline 
 
For this pathogen, 
addition of one of the 
following agents is 
usually recommended:  
Vancomycin 
Linezolid 
Daptomycin 
Oritavancin 
Dalbavancin  
Doxycycline 
Trimethoprim/    
sulfamethoxazole 
Doxycycline 
Piperacillin/tazobactam 
Meropenem 
Ertapenem 
Imipenem/cilastatin 
Amoxicillin/clavulanate  
Ampicillin/sulbactam 
 
For this group of 
pathogens,  
metronidazole or 
clindamycin may be 
added to a beta-lactam 
therapy that does not 
cover anaerobes (e.g., 
ceftriaxone, cefepime) 
 
METHODS 
  
Participants 
This was a cohort study of patients who were enrolled in the OPAT program at the University of 
North Carolina Medical Center (UNCMC; Chapel Hill, NC) between January 2015 and 
September 2018. The University of North Carolina institutional review board approved this 
study. Patients were included in the study if they were discharged from UNCMC and were 
enrolled in the OPAT program for treatment of diabetic foot infection or osteomyelitis, and 
received either ceftriaxone, cefepime, ertapenem, meropenem, or piperacillin-tazobactam. These 
beta-lactam therapies were chosen because of their high frequency of use among patients 
enrolled in the OPAT program at UNCMC. Patients could enroll in multiple courses of OPAT, 
but because multiple enrollments were rare in this setting, we studied them as temporally 
distinct. 
 
UNC OPAT Definitions and Requirements 
The UNC OPAT program requires a referral and completed template from the Inpatient 
Infectious Diseases Consult Services or dedicated Infectious Diseases medicine service sent to 
the OPAT physician and pharmacist team. Additional enrollment criteria included: patient 
referral received at least 24 hours before discharge, enrollment in home infusion services, and 
planned duration of intravenous therapy ≥ 2 weeks. Patients are not eligible for the UNC OPAT 
program if they have end stage renal disease and require dialysis, will be discharged to a skilled 
nursing facility, or if they have a history of intravenous drug use. 
 
Objectives 
The primary outcome was time-to-first ADR during OPAT therapy for any of the medications 
included in the study. Secondary outcomes included ADR types and frequencies observed among 
patients treated with beta-lactam alone or with concomitant vancomycin or daptomycin, rate of 
hospital readmission and medication change due to ADR. 
 
Data Collection 
Data extracted included patient demographics, comorbidities, concomitant medications, 
antimicrobial therapy administered, treatment indication, outpatient laboratory monitors, 
duration of OPAT enrollment, hospital readmission due to ADR, and change in medication due 
to ADR. 
 
Data were collected using Research Electronic Data Capture database software application 
(North Carolina Translational and Clinical Services Institute, Chapel Hill, NC) and analyzed 
using SAS Version 9.4 (SAS Institute., Cary, NC). 
 
Adverse Drug Reactions 
The definitions of the specific ADRs included in the study are found in Table 2. ADRs were only 
included if they met the standardized criteria, and were confirmed by a physician or member of 
the OPAT Team (not simply patient-reported). For each patient, only the first ADR experienced 
was included, although patients who experienced multiple ADRs on the same day were reported 
as having both ADRs. A Kaplan-Meier curve was constructed to analyze the time-to-first ADR 
on any beta-lactam therapy over 8 weeks (56 days) of therapy. 
Table 2. Definitions of adverse drug reactions 
Adverse Drug Reaction Definition 
Nephrotoxicity Increase in SCr > 0.5 mg/dL or 50% increase 
Thrombocytopenia Platelets < 100 x103 cells/mm3 and > 50% decrease in 
platelet count 
Neutropenia Absolute neutrophil count (ANC) < 1000 cells/mm3 
Hepatotoxicity ALT > 100 U/L 
Eosinophilia Eosinophil count (EOS) > 500 µL 
Abbreviations: SCr, serum creatinine; ALT, alanine aminotransferase 
 
 
 
 
RESULTS 
 
A total of 178 patients received 193 OPAT courses, and multiple OPAT enrollments were 
allowed. Baseline characteristics are listed in Table 3. Of the 193 OPAT courses, 29% were 
given to patients who received antimicrobial therapy for treatment of both diabetic foot infection 
(DFI) and osteomyelitis (OM), 2% of courses were indicated for only DFI, and 69% of courses 
were indicated for treatment of only OM. Ertapenem and cefepime were the most commonly 
prescribed beta-lactam therapies. Patients received a median of 42 days (IQR range 38 to 50 
days) of total (inpatient and planned outpatient) antimicrobial treatment. Table 3 lists the 
baseline characteristics of all patients enrolled in the study.  
 
 
Table 3: Baseline Characteristics of 193 courses of outpatient parenteral antimicrobial therapy 
among 178 distinct patients (multiple enrollments allowed) 
Characteristic Number 
OPAT Indication: 
 Diabetic Foot Infection 3 (2%) 
 Osteomyelitis 134 (69%) 
 Both 56 (29%) 
Beta-Lactam Therapy (n = 333 courses) 
 Ceftriaxone 41 (21%) 
 Cefepime 2 (15%) 
 Piperacillin/tazobactam 30 (16%) 
 Ertapenem 76 (39%) 
 Meropenem 17 (9%) 
Duration of therapy (days), (median, IQR) 42 (38-50) 
Concomitant therapies: 
 Vancomycin 76 (39%) 
 Daptomycin 31 (16%) 
 
 
 
 
 
The primary outcome was time-to-first ADR during OPAT therapy for any of the medications 
included in the study Risk of any ADR within the first 8 weeks of therapy with either 
ceftriaxone, cefepime, ertapenem, meropenem, or piperacillin-tazobactam was 40% (95% CI 29 
to 48%), as shown in Figure 1. 
 
 
 
Figure 1: Cumulative risk of ADR among OPAT patients initiated on beta-lactam therapy for 
OM and/or DFI, 2015-2018 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The secondary outcome of this study was to identify the types and frequencies of ADRs during 
OPAT therapy. There were a total of 78 adverse drug events that were documented in 53 (30%) 
of the 178 patients. Of the ADRs that occurred, there were 24 (31%) occurrences of 
nephrotoxicity, 19 (24%) occurrences of eosinophilia, 13 (17%) occurrences of hepatotoxicity, 
10 (13%) occurrences of rash, 9 (12%) occurrences of neutropenia, and 3 (4%) occurrences of 
thrombocytopenia. Overall, there were 55 distinct OPAT courses that resulted in an ADR. 
Among these, 8 courses (10%) required that patients be readmitted due to the effects of the 
adverse drug reaction (ADR), and 33 (81%) courses required a change in medication therapy due 
to the ADR. Vancomycin was the most common concomitant antibiotic among OPAT 
enrollments, with 76 (39%) courses receiving concomitant vancomycin and 31(16%) courses 
receiving daptomycin. Table 4 lists the data collected for those OPAT courses that resulted in an 
adverse drug reaction (n=55). Figure 2 describes the specific ADRs experienced by patients on 
different beta-lactam therapies. 
 
Table 4: Frequency of ADR associated with beta-lactam therapies and outcomes (n= 55 courses 
associated with at least one ADR among 53 distinct patients) 
Characteristic Frequency/ 
Denominator 
Risk (%) 
Any Beta-Lactam   
 Ceftriaxone 11/41 27% 
 Cefepime 8/29 28% 
 Piperacillin/tazobactam 12/30 40% 
 Ertapenem 18/76 24% 
 Meropenem 6/17 35% 
Hospital Readmission due to ADR 8/55 17% 
Change in medication due to ADR 33/55 67% 
 
 
 
 
 
 
Figure 2: Types of ADRs associated with beta-lactam therapies, n=78 ADRs among 53 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
In this study of 178 patients receiving OPAT for diabetic foot infection and osteomyelitis, 30% 
of patients experienced adverse drug reactions, which is similar to rates in previous studies6,8.  
Over one in four patients treated with one of the study beta-lactams experienced an ADR by 8 
weeks of therapy. Ertapenem and cefepime were the most commonly prescribed beta-lactam 
therapies. Patients receiving piperacillin/tazobactam had the highest incidence of ADRs per 
exposure (40%). Vancomycin was the most common concomitant antibiotic among patients 
enrolled in OPAT (39%), followed by daptomycin (16%).  Further analysis will be needed to 
determine what role vancomycin and daptomycin may play in increasing the risk of experiencing 
an ADR on dual therapy. Most patients who experienced an ADR required a change in therapy,  
and one-third of total OPAT courses resulting in an ADR required readmission as a result (17%); 
this means that if risk is actually different among beta-lactams, safer drugs will prevent 
avoidable complications.  
 
While OPAT is an increasingly used practice, there are currently no evidence-based 
recommendations that exist on patient education, care transition, frequency of outpatient 
monitoring or follow-up for patients enrolled in an OPAT program.5 Additionally, there is a lack 
of data regarding comparative safety of long durations of antimicrobials in outpatient settings. 
When empirical therapy is required for treatment of DFI or OM, the different safety profiles of 
beta-lactam therapies in an outpatient setting can assist clinicians in drug selection. For example, 
if Pseudomonas coverage is indicated in a patient who will be receiving OPAT, it may be 
reasonable to select cefepime or meropenem rather than piperacillin-tazobactam due to the 
differences in ADR risk among those therapies. Or, if two agents have comparable ADR risk, 
such as ceftriaxone and ertapenem for non-Pseudomonas coverage, selection of one beta-lactam 
therapy over another might be based on other factors, such as cost or an additional need for 
anaerobic coverage. This study provides a fresh perspective on choosing antimicrobial therapy 
for infections such as DFI and OM where there is not substantial evidence to guide selection of 
therapy in the outpatient setting. 
 
Limitations of this study include its retrospective, single-center design, and readmissions to other 
hospitals were not captured. Future studies using the collected data will look at the comparative 
safety of beta-lactam therapy alone versus with concomitant antimicrobials that may influence 
the development of ADRs, such as vancomycin and daptomycin. Additionally, the safety of these 
therapies will be adjusted for based on concomitant medications (e.g. nephrotoxicity in patients 
receiving ADRs and NSAIDs), and the patients’ Charlson Comorbidity Index scores, to assess if 
there is a correlation between these factors and occurrence of ADRs.  
 
A multidisciplinary approach to managing patients who are enrolled in OPAT programs allows 
for efficient monitoring and response to potential complications that may arise during therapy. 
Specifically, a pharmacist as part of an OPAT team can play a valuable role in the review and 
monitoring of adverse effect profiles of specific antimicrobial therapies. As standard medical 
practices, such as parenteral antimicrobial therapy, continue to be pushed to the ambulatory care 
setting in the changing climate of health care, additional studies are needed to help avoid 
preventable complications and readmissions that can occur in these outpatient settings.  
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